Galectin Therapeutics (GALT) Receivables (2010)

Galectin Therapeutics (GALT) posted quarterly Receivables of $234000.0 for Q4 2010.

Galectin Therapeutics (GALT) Receivables (2010) Analysis & Trends

Galectin Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $234000.0 for Q4 2010.

In Q4 2010, Receivables changed N/A year-over-year to $234000.0; the TTM figure through Dec 2010 stood at $234000.0 (changed N/A YoY), while the FY2010 annual figure was $468000.0, changed N/A from the prior year.
Receivables for Q4 2010 stood at $234000.0.
The five-year high for Receivables was $234000.0 in Q4 2010, with the low at $234000.0 in Q4 2010.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Galectin Therapeutics	226.55 Mn	226.55 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2010	234,000.00